Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

GUANFACINE

All products: Limited Use (codes 540)

Intuniv XR · DIN 02409119 · 2mg · extended release tablet

Limited Use — Reason for Use code 540 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 540 required
Write on scriptLU code 540 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 540
Reason for Use code 540 For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 to 17 years who meet the following criteria: (i) As adjunctive therapy to psychostimulants; OR (ii) As monotherapy in patients who have significant intolerance to psychostimulants AND who have had an inadequate response to either atomoxetine or other non-stimulant alternative(s). Coverage limit: LU Authorization Period: 1 year
Savings card: innoviCares lists Intuniv XR (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Intuniv XR · DIN 02409119 Manufacturer: Takeda Canada Inc.; listing date 2020-01-31 Health Canada: Marketed since 2021-07-29 · brand INTUNIV XR · ATC C02AC02 GUANFACINE · form Tablet (extended-release) · route Oral · ingredients GUANFACINE (GUANFACINE HYDROCHLORIDE) 2 MG · company Takeda canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.9353 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89384 · Verify on the e-Formulary ↗ (DIN 02409119)

Source record
DIN 02409119: Intuniv XR Raw flags: sec12=Y, sec3=Y Item: 240816002; group id 360; item number 0841; lccId 00326; manufacturer id TAK Source form: ER Tab; strength: 2mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.7413; ministry $0.9353 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02409119 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89384
Interchangeable products
Apo-Guanfacine XR · DIN 02523736 · $0.9353 Jamp Guanfacine XR · DIN 02523566 · $0.9353 Sandoz Guanfacine XR · DIN 02563193 · $0.9353
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02409119
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (24:08:16 Central Alpha-Agonists) and how they are covered
No products matched this class search: “24:08:16”. This is a search result, not a decision about coverage. Try a different class name, abbreviation or class code. Search this as a medication name or DIN
Full class listing Related classes: 24:06:24 PCSK9 Inhibitors, 24:32:08 Angiotensin II Receptor Antagonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: an integral part of a total treatment program for adhd that may include other measures, attention deficit hyperactivity disorder
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: DEXTROAMPHETAMINE SULFATE, MIXED SALT AMPHETAMINE DEXTROAMPHETAMINE SULFATE · General benefit 1 INDICATIONS DEXEDRINE/DEXEDRINE SPANSULE (dextroamphetamine sulfate) is indicated: • in the adjunctive treatment of narcolepsy • for the treatment of attention deficit hyperactivity disorder (ADHD) Attention Deficit Hyperactivity Disorder (ADHD): A diagnosis of ADHD (DSM-IV) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and that were present before age 7 years. PM: https://pdf.hres.ca/dpd_pm/00083629.PDF; date FEB 25, 2026; DIN 01924516; fetched 2026-09-10 Product monograph Need for Comprehensive Treatment Program: DEXEDRINE/DEXEDRINE SPANSULE is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational and social) for patients with this syndrome. PM: https://pdf.hres.ca/dpd_pm/00083629.PDF; date FEB 25, 2026; DIN 01924516; fetched 2026-09-10 Product monograph MIXED SALT AMPHETAMINE · General benefit Indications ADDERALL XR (mixed salts amphetamine extended-release capsules) is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in: • Children (6 – 12 years of age) • Adolescents (13 – 17 years of age) • Adults (18 years of age or older) Need for Comprehensive Treatment Program ADDERALL XR is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. PM: https://pdf.hres.ca/dpd_pm/00081719.PDF; date 2025-09-12; DIN 02248808; fetched 2026-09-10 Product monograph ATOMOXETINE HCL · Listed, not a benefit (5), General benefit (40), Off-Formulary Interchangeable, not an ODB benefit (14) Need for Comprehensive Treatment Program TEVA-ATOMOXETINE is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social) for patients with this syndrome. PM: https://pdf.hres.ca/dpd_pm/00052053.PDF; date July 2, 2019; DIN 02314541; fetched 2026-09-10 Product monograph LISDEXAMFETAMINE DIMESYLATE · General benefit (54), Off-Formulary Interchangeable, not an ODB benefit (6) Need for Comprehensive Treatment Program VYVANSE is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational/vocational, social) for patients with this syndrome. PM: https://pdf.hres.ca/dpd_pm/00081828.PDF; date 2025-09-15; DIN 02322951; fetched 2026-09-10 Product monograph METHYLPHENIDATE HCL · General benefit (43), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (3) INDICATION AND CLINICAL USE pms-METHYLPHENIDATE is indicated for the treatment of:  Attention Deficit Hyperactivity Disorder (ADHD) Need for Comprehensive Treatment Program pms-METHYLPHENIDATE is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. PM: https://pdf.hres.ca/dpd_pm/00068339.PDF; date October 17, 2022; DIN 00584991; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications Pediatrics (6 to 17 years of age) INTUNIV XR (guanfacine hydrochloride extended-release tablets) is indicated as: • monotherapy for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. • adjunctive therapy to psychostimulants for the treatment of ADHD in children and adolescents, aged 6 to 17 years, with a sub-optimal response to psychostimulants. Adults (>18 years of age): INTUNIV XR has not been systematically studied in and is therefore not indicated for use in adults (over 18 years of age). Need for Comprehensive Treatment Program INTUNIV XR is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational/vocational, social) for patients with this syndrome. Drug treatment may not be indicated for all patients with this syndrome. Drug treatment is not intended for use in a patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational/vocational placement is essential for patients with this diagnosis and psychosocial interv… https://pdf.hres.ca/dpd_pm/00082036.PDF PM date: not printed or not captured Source product: INTUNIV XR; DIN 02409100; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.